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Transposons  are  promising  systems  for  somatic  gene 
integration because they can not only integrate exog-
enous genes efficiently, but also be delivered to a variety 
of organs using a range of transfection methods. piggy-
Bac (PB) transposon has a high transposability in mam-
malian cells in vitro, and has been used for genetic and 
preclinical studies. However, the transposability of PB in 
mammalian somatic cells in vivo has not been demon-
strated yet. Here, we demonstrated PB-mediated sus-
tained gene expression in adult mice. We constructed 
PB-based  plasmid  DNA  (pDNA)  containing  reporter 
[firefly and Gaussia luciferase (Gluc)] genes. Mice were 
transfected by injection of these pDNAs using a hydro-
dynamics-based  procedure,  and  the  conditions  for 
high-level  sustained  gene  expression  were  examined. 
Consequently, gene expressions were sustained over 2 
months. Our results suggest that PB is useful for organ-
selective somatic integration and sustained gene expres-
sion in mammals, and will contribute to basic genetic 
studies and gene   therapies.
Received 29 June 2009; accepted 10 December 2009; published online 
26 January 2010. doi:10.1038/mt.2009.302
IntroductIon
Nonviral vectors for gene transfer are promising tools for genetic 
studies and therapies because of their high productivity and high 
safety.1,2 Because conventional plasmid DNA (pDNA)-based non-
viral vectors have no tendency for chromosomal integration, gene 
expression from these vectors is transient. However, some diseases 
such as hereditary or chronic diseases need sustained therapeutic 
gene expression.
One of the approaches to overcome this limitation is utiliza-
tion of transposons.3 Transposons are mobile genetic elements 
that transpose between or within vectors, and chromosomes. In 
this  transposition,  transposase  recognizes  transposon-specific 
inverted terminal repeat sequences (IRs) located on both ends of 
the transposons, and removed from their original sites and inte-
grated into other sites. Because of this feature, transposons con-
taining genes of interest between their two IRs are able to carry the 
genes from vectors to chromosomes.
The transposability of a few transposons has been demonstrated 
in mammalian cells. After molecular reconstruction of Sleeping 
Beauty (SB) transposon,4 SB has been widely used for mamma-
lian genetic5,6 and preclinical studies7 because of its high transpos-
ability in mammalian cells. Recently, piggyBac (PB), a transposon 
derived from cabbage looper moth Trichoplusia ni,8 was shown to 
transpose more efficiently than other transposons including Tol2 
(refs. 9,10), passport,10 and two hyperactive versions of SB9–11 in 
mammalian cells. In addition, PB can integrate up to 9.1 kilobases 
(kb) of foreign sequence without significant reduction in trans-
position efficiency,12 whereas the transposition efficiency of SB is 
reduced in a size-dependent manner (about 50% when the size of 
transposon reaches 6 kb).13 Because of its high cargo capacity and 
high transposition efficiency in mammalian cells, PB is regarded 
as a promising tool for basic genetic studies and gene therapies. PB 
has been used for chromosomal integration in mammalian germ 
lines,12 embryonic stem cells,14 and tumor xenograft.15 In addition, 
PB has also been used for induction of pluripotency.16–18 However, 
the transposability of PB in mammalian somatic cells in vivo has 
not been demonstrated yet. An in vivo transposition investiga-
tion of PB is needed for in vivo genetic applications, such as pre-
clinical studies of gene therapies or organ-specific tumor model 
establishment.19,20
In the present study, we investigated and demonstrated PB-
mediated sustained gene expression in adult mice in vivo. At first, 
we constructed PB-based pDNA containing reporter [firefly and 
Gaussia luciferase (Gluc)] genes. Mice were transfected by injec-
tion of these pDNAs using a hydrodynamics-based procedure, 
and the conditions for sustained gene expression were optimized. 
Consequently, gene expressions were sustained over 2 months. 
Our results suggest that PB is useful for organ-selective somatic 
integration and sustained gene expression in mammals, and will 
contribute to basic genetic studies and gene therapies.
results
transposition in human hepatocyte-derived cell lines
Initially, we created two pDNAs. One contains an expression cas-
sette of PB transposase (pFerH-PBTP), whereas the other contains 
expression  cassettes  of  firefly  luciferase  (Fluc)  and  neomycin-
  resistance genes flanked with PB IRs and internal sequences nec-
essary  for  efficient  chromosomal  integration21  (pIR-CMVluc) 
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(Figure 1). To examine the transposition activity by the constructed 
pDNAs, we transfected these pDNAs to human hepatocellular 
liver carcinoma cell lines, HepG2 and Hep3B. We selected these 
cells because the liver is the major target organ of hydrodynam-
ics-based transfection procedure.22,23 To investigate chromosomal 
integration and sustained expression of neomycin-resistance gene, 
transfected cells were incubated in G418-containing medium for 
2 weeks. The transposase groups (pIR-CMVluc and pFerH-PBTP) 
of HepG2 and Hep3B formed 147-fold and 71-fold more colonies 
than the control groups (pIR-CMVluc and negative control pDNA; 
pFerH-mcs; Figure 1), respectively (Figure 2a–c). In addition, 
these colonies showed luciferase luminescence (Figure 2d). These 
results indicated that both Fluc and neomycin-resistance genes 
were integrated into chromosomes by the constructed pDNAs in 
mammalian hepatocyte-derived cells.
Prolonged firefly luciferase expression in vivo
We next transfected these pDNAs to adult mice by a hydrodynamics-
based procedure to determine the transposability of PB in vivo. 
Because  expression  by  this  procedure  in  liver  is  much  higher 
(>1,000-fold) than that in other organs,22 we measured Fluc expres-
sion in livers. The Fluc activity of the transposase group (pIR-CM-
Vluc and pFerH-PBTP) did not decrease from 5 to 8 days after 
transfection, whereas that of the control group (pIR-CMVluc and 
pFerH-mcs) decreased to about 1/4 during the same time period 
(Figure 3a). PB transposase did not increase expression from con-
ventional pDNA under these experimental   conditions both 1 and 
8 days after transfection (Figure 3b).
Prolonged secreted protein expression in vivo
For a longer investigation of PB-mediated sustained exogenous 
gene expression, we next created another pDNA containing the 
Gluc24  expression  cassette  flanked  with  PB  IRs  and  the  same 
internal sequences as pIR-CMVluc (pIR-CMVGluc) (Figure 1). 
We selected Gluc because it is secreted in blood and enables con-
tinuous measurement of the expression level in the same mice,25 
and because it can be expressed without being compromised by 
  neutralizing antibodies for at least 3 weeks.26 In addition, because 
the half-life of Gluc in blood is about 20 minutes,25 Gluc activity in 
serum correlates well with the real-time expression. In the trans-
posase group (pIR-CMVGluc and pFerH-PBTP), the Gluc expres-
sion decreased rapidly until 1 day after transfection, but the rate 
of decrease became slow, and Gluc expression was still detected 
at 80 days after transfection. In contrast, in the control group 
(pIR-CMVGluc  and  pFerH-mcs),  Gluc  expression  decreased 
rapidly until 7 days after transfection by which time the Gluc 
expression had reached background level (Figure 4a). As in the 
case of Fluc, PB transposase did not affect Gluc expression from 
conventional pDNA (pCMV-Gluc; Figure 1) (Figure 4b). These 
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Figure 2  sustained gene expression in vitro. (a,b) In vitro transpo-
sition study. Hep3B (a) and HepG2 (b) cells (2 × 105 cells/well) were 
transfected with 0.67 µg pIR-CMVluc and 0.33 µg pFerH-mcs (left bar) or 
pFerH-PBTP (right bar). The number of colonies was counted by methy-
lene blue staining after 2 weeks’ selection with G418. Each value rep-
resents the mean ± SD (n = 4). (c,d) An image of Hep3B colonies. The 
colonies were stained with methylene blue (c). 0.3 mmol/l d-luciferin 
was added to the colonies (d). Both images were captured after 2 weeks’ 
selection with G418.
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Figure 3  sustained Fluc expression in vivo. Expression time course of 
Fluc from PB-based (a) or conventional (b) pDNA. 25 µg pIR-CMVluc and 
1 µg pFerH-PBTP (gray bar) or pFerH-mcs (white bar) were injected (a). 
25 µg pCMV-luc and 1 µg pFerH-PBTP (gray bar) or pFerH-mcs (white 
bar) were injected (b). After pDNA injection, livers were collected at 
the indicated time points, and Fluc activities were measured. Each value 
represents mean ± SD (n = 4–8). RLU, relative light unit.
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Figure 1  Plasmid dnA construction. BlastR, blasticidin-resistance gene; 
CMV,  cytomegalovirus  promoter;  EF1α,  human  elongation  factor  1α 
promoter; EM7, bacterial EM7 promoter; Fluc, firefly luciferase gene; 
Gluc, Gaussia luciferase gene; hFerH, human ferritin heavy chain pro-
moter; HGF, human hepatocyte growth factor gene; NeoR, neomycin-
resistance  gene;  PBIR;  piggyBac  terminal  inverted  repeat  sequence; 
PBTP, piggyBac transposase gene; SV40, simian virus 40 promoter; ori, 
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results indicated that expression from pDNA containing PB IRs is 
  prolonged over 2 months by PB transposase in mice.
effect of promoters on gene expression in vivo
Although  Gluc  expression  from  pIR-CMVGluc  was  prolonged 
when pIR-CMVGluc was co-transfected with pFerH-PBTP, Gluc 
expression  decreased  gradually.  We  assumed  that  the  gradual 
decrease in Gluc expression resulted from postintegrative gene 
silencing  because  the  CMV  promoter  is  susceptible  to  gene 
  silencing.27  A  previous  study  about  the  postintegrative  gene 
silencing of SB showed that the EF1 promoter was less suscep-
tible to postintegrative gene silencing.28 Therefore, we created a 
new pDNA (pIR-EF1Gluc; Figure 1) by exchanging the CMV 
promoter of pIR-CMVGluc for the human EF1 promoter. In the 
transposase group (pIR-EF1Gluc and pFerH-PBTP), Gluc expres-
sion decreased until 10 days after transfection, but no apparent 
decrease was observed from 10 to 55 days after transfection. In 
contrast,  in  the  control  group  (pIR-EF1Gluc  and  pFerH-mcs), 
Gluc expression resulted in a near background level at 14 days 
after transfection (Figure 4c).
Molecular confirmation of transposition
To confirm that chromosomal integration resulted from transpo-
sition and not from recombination, we performed plasmid exci-
sion assay using PCR. In transposition, PB transposon is excised 
from donor plasmid before integration. Therefore, if transposition 
occurred, the shorter version of the donor plasmid should be pro-
duced (Figure 5a). The excision-dependent PCR products were 
detected only in the transposase groups both in Hep3B, HepG2 
(Figure 5b), and mouse livers (Figure 5c). These results suggested 
that chromosomal integration resulted from transposition.
For further confirmation of transposition, we examined the 
sequence of integration sites by plasmid rescue. In accord with 
previous studies,9–12 PB was integrated into only TTAA sequences 
(Table 1).
effect of the amount of transposase on  
transposition in vitro
We next investigated the effect of the amount of pFerH-PBTP with 
regard to the transposition efficiency in vitro. The number of G418-
resistant colonies increased in a pFerH-PBTP-dependent manner 
over the range of 0–250 ng, but a further increase in pFerH-PBTP 
to 500 ng resulted in a decrease in the number of G418-resistant 
colonies in both 1 × 105 HepG2 and Hep3B (Figure 6a,b). To 
examine whether the cytotoxicity of transposase contributed to 
this decrease, we investigated the cell viability with a constant 
amount  of  pIR-CMVluc  and  an  increasing  amount  of  pFerH-
PBTP. The cell viability decreased in a pFerH-PBTP-  dependent 
manner  (Figure  6c).  In  addition,  we  also  examined  whether 
the cytotoxicity depends on transposase itself or transposition 
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Figure 4  sustained Gluc expression in vivo. Expression time course of 
Gluc from PB-based (a,c) or conventional (b) pDNA. 25 µg pIR-CMVGluc 
and 1 µg pFerH-PBTP (closed rhombuses), or pFerH-mcs (closed squares) 
were injected (a). 25 µg pCMV-Gluc and 1 µg pFerH-PBTP (closed rhom-
buses), or pFerH-mcs (closed squares) were injected (b). 25 µg pIR-EF1-
Gluc and 1 µg pFerH-PBTP (closed rhombuses), or pFerH-mcs (closed 
squares) were injected (c). Blood samples were collected at the indicated 
time points, and Gluc activities in serum were measured. Each value 
  represents mean ± SD (n = 4–6). RLU, relative light unit.
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catalyzed by transposase. When pFerH-PBTP was co-transfected 
with conventional pDNA (pCMV-luc), the cell viability slightly 
decreased, but no statistical significance was observed. In contrast, 
when pFerH-PBTP was co-transfected with pIR-CMVluc, the cell 
viability decreased with statistical significance. These results sug-
gest that the cytotoxicity may be partially caused by transposase 
itself, but mainly caused by transposition.
effect of the amount of transposase on  
transposition in vivo
To investigate the ideal amount of pFerH-PBTP in vivo, we co-
transfected mice with a constant amount of 25 µg pIR-EF1Gluc 
and a variable amount of pFerH-PBTP from 1 to 50 µg using the 
hydrodynamics-based transfection procedure. The sustained Gluc 
expression level increased in a pFerH-PBTP-dependent manner 
over the range of 1–25 µg, but a further increase in pFerH-PBTP 
to 50 µg resulted in a reduction of the sustained Gluc expression 
level (Figure 7).
dIscussIon
Here, we demonstrated that PB can prolong gene expression from 
pDNA in vivo. Exogenous gene expression was prolonged by PB 
transposase in vivo only when pDNA contains PB IRs (Figures 3 
and 4). When we injected PB-based pDNA containing Gluc gene 
under EF1 promoter control, expression levels did not apparently 
decrease from 10 days after injection (Figure 4c). These results 
support a previous report showing that an SB-based pDNA con-
taining human factor IX under EF1 promoter control succeeded 
in producing long-lasting expression without apparent decrease in 
the expression level.29
It  was  previously  reported  that  gene  expression  from  con-
ventional  pDNA  containing  mammalian  promoters  persists 
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table 1  piggyBac integration sites in Hep3B cells
location sequence refseq gene
Chr9 (p13, 3) TTAAAAGGGTAGGAATAAGCAGTCTAATTCAGACATACTTTGTATAGGGG… RUSC2
Chr18 (q21, 33) TTAAACATTATATATCCTTAGGGAGTTTCAAATTAAGACAACACTGAGAT… —
Chr2 (p16, 1) TTAAATAAATTTGCACGCTTTTCTCTTATTAATCTGTCTTTTCTTATAAGGG… —
Chr21 (q21, 1) TTAAACAATTACTAGCTGTCAAAATCTGTGCTTGGGACATTTATATTTCAA… —
Chr10 (q23, 31) TTAATGAAGCTTATAAATGGCAAAAAGCAAAGTAAGTACAGTAAATGCT… PANK1
Chr15 (q25, 2) TTAAACAGATATTTCTCAAAAGAAGGCATAGAAATGCCCAACAGTATATG… —
Chr6 (p22, 3) TTAAACGCTCAACGAGTAACAGGGTATGTCGATGAATTCTGATTTTTTTTC… —
Chr8 (p22) TTAATATTGTATAAATGTTGGAATTCTTGTTTATGCCAAGGTGGACAACAAC… MTUS1
Chr1 (q31, 2) TTAACAAAGGTACGTATTATACATTGTCATACTATTTCTCAAAAACATTATT… —
Columns 1–3 show chromosome numbers and locations, sequences, and RefSeq genes of integration sites, respectively. All sequences were determined by plasmid 
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longer  than  pDNA  containing  viral  promoters.27  In  our  study, 
although expression from PB-based pDNA containing Gluc gene 
under CMV promoter control was prolonged, Gluc expression 
decreased gradually. In addition, when pDNA containing PB IRs 
was injected without pFerH-PBTP, Gluc expression by EF1 pro-
moter was detected 10 days after injection, whereas that by CMV 
promoter  had  reached  background  level  7  days  after  injection 
(Figure 4a,c). These results and previous studies27,28 suggest that 
mammalian promoters (ubiquitin C and EF1) are less suscepti-
ble to gene silencing than viral promoters,28 and tend to express 
longer than viral promoters (CMV, RSV, and SV40)27,28 not only 
in the episomal state27 but also when integrated by transposons 
(Figure 4).28 Therefore, mammalian promoters could be suitable 
for sustained gene expression regardless of whether the vectors are 
integrative or not.
Sustained Gluc expression ranged from 0.8 to 5.3% of the 
initial  Gluc  expression  (Figure  7b).  However,  the  initial  Gluc 
expression may not reflect the actual amount of the expression 
cassette  because  the  hydrodynamics-based  procedure  activates 
transcription.30 Therefore, the initial expression may be lower if 
transcription  was  not  highly  activated  by  the  hydrodynamics-
based procedure and the actual percentage of integration may 
be higher than the percentage shown in Figure 7b. Interestingly, 
Gluc  expression  became  stable  earlier  in  higher  pFerH-PBTP 
groups (Figure 7a). The initial decrease in Gluc expression may 
be partially explained by the decrease in the remaining episomal 
expression cassettes. Therefore, this earlier stabilization of Gluc 
expression in higher pFerH-PBTP groups may be due to fewer 
remaining episomal expression cassettes. In addition, the peak 
expression was also higher when more pFerH-PBTP was trans-
fected (Figure 7a). This may result from more efficient expression 
from chromosomes than from pDNA.
Although IRs of PB possess promoter or enhancer effects,31,32 
the initial expressions from pIR-CMVluc and pIR-CMVGluc were 
lower than those from pCMV-luc and pCMV-Gluc, respectively 
(Figures 3a,b and 4a,b). These differences may be explained by 
the differences of plasmid backbones. For example, the number 
of CG motif, which may cause gene silencing, in pIR-CMVluc 
is about one hundred more than that in pCMV-luc. Because the 
construct outside of the transposon is not necessary for transposi-
tion, transferring the transposon into other constructs could solve 
this lower expression. Although SB transposase was reported to 
increase expression from conventional pDNA,33 PB transposase 
did not affect expression from conventional pDNA in our experi-
mental conditions (Figures 3b and 4b).
In the case of some transposons including SB, transposition effi-
ciency decreases in the presence of an excess of transposase.9,11,13,29 
This decrease is called “overproduction inhibition.” A decrease 
in transposition efficiency could result in a low level of sustained 
transgene expression29 and therapeutic effect. Avoiding “overpro-
duction inhibition” and identifying the ideal amount of trans-
posase expressing pDNA may be necessary to achieve high-level 
sustained transgene expression. In our study, both the numbers 
of  colonies  in  vitro ( Figure  6a,b)  and  sustained  gene  expres-
sion levels in vivo (Figure 7a,b) decreased in the presence of an 
excess of pFerH-PBTP. In addition, cell viability decreased when 
the  amount  of  tranfected  pFerH-PBTP  increased  (Figure  6c). 
Although it is still unclear whether other factors such as trans-
posase–transposase interaction can contribute to the decrease of 
the numbers of colonies and sustained expression level, this result 
suggests that the cytotoxicity of PB transposase can partially con-
tribute to the decrease of sustained gene expression level. From 
this  viewpoint,  high  transfection  efficiency  may  increase  the 
amount of PB transposase and decrease sustained gene expres-
sion levels. Moreover, the promoter strength in transfected cells 
may also affect sustained gene expression level. Because transcrip-
tion factor expression may differ among cell types, cell types may 
affect not only the transfection efficiency but also the transcrip-
tion activity of promoters controlling transposase expression. In 
a previous study showing “overproduction inhibition” of PB,9 the 
maximal number of colonies was about 5,000 when the amount of 
transposase was increased. On the other hand, in two other stud-
ies showing no “overproduction inhibition” of PB,11,31 the maximal 
number of colonies was about 400 and 100, respectively, when the 
amount of transposase was increased. This difference also sug-
gests that a higher transfection efficiency could induce “overpro-
duction inhibition.” The transfection efficiency is affected by both 
the transfection methods and the cell types. Therefore, adjust-
ment of the optimum amount of transposase for each transfection 
method and cell type may be needed to achieve high transposition 
efficiency.
Transposon-based vectors still have problems for therapeu-
tic applications because transposons can integrate into or nearby 
the coding region, and affect endogenous gene expression. In the 
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Figure 7  effect of the amount of transposase versus the transposi-
tion in vivo. (a) Expression time course. Mice were injected with 25 µg 
pIR-EF1Gluc and 1 (open rhombuses), 5 (open squares), 10 (open tri-
angles), 25 (closed rhombuses), and 50 (closed squares) µg pFerH-PBTP, 
respectively.  Blood  was  collected  at  the  indicated  time  points,  and 
Gaussia luciferase activity in serum was measured. Each value represents 
the mean ± SD (n = 4–6). (b) Percentage of sustained gene expres-
sion. Gaussia luciferase activities 78 days after injection were divided by 
those 1 day after injection and multiplied by 100. Each value represents 
the mean ± SD (n = 4–6). *t-test statistically different (P < 0.05) from the 
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case of integrative viral vectors, cancer produced by   insertional 
  mutagenesis  has  been  reported.34  Although  PB  has  a  lower 
  tendency to integrate into or nearby genes than lentivirus, the 
tendency of PB to integrate into or nearby genes is higher than 
random integration and SB,11 and the risk of insertional muta-
genesis remains. Site-specific integration using sequence-  specific 
DNA-binding  proteins  is  one  approach  to  avoid  insertional 
mutagenesis.35–37 PB is suitable for site-specific integration because 
DNA-binding  protein-transposase  chimera  is  active  as  native 
transposase, whereas the chimeric transposase of SB and Tol2 is 
inactive9 or low active.36,37 Moreover, the chimeric PB transposase 
was reported to integrate 67% of PB transposons into a single tar-
get site on a pDNA in mosquito embryos.35
During preparation of this article, a new hyperactive SB trans-
posase  named  SB100X,  which  has  higher  transposability  than 
PB, has been reported.38 Because use of PB for mammals is rela-
tively new, such hyperactive versions of PB transposase have not 
been reported yet. However, PB may be improved as use of PB 
increases.
In the present study, we used a hydrodynamics-based proce-
dure to introduce transposon-based pDNA into mice. Systemic 
injection of such a high volume solution is not suitable for clinical 
applications. However, the organ-restricted hydrodynamics-based 
procedure that injects solution into a specific vein of an expand-
able organ using a balloon catheter may be suitable for clinical 
treatment.2 In contrast to viral vectors, transposon-based pDNA 
can be transfected by various conventional nonviral methods such 
as lipoplex, polyplex, electroporation, and mechanical massage.1,2 
Therefore, transposon-based pDNA can easily be adapted to a 
variety of organs such as the lung,39,40 liver,29 kidney,41,42 or spleen43 
using a suitable transfection method for each target, whereas the 
targets of viral vectors may be limited by the nature of each virus. 
In addition, when the target organs are susceptible to some viral 
vectors, the transposon can also be loaded on viral vectors such 
as  adenovirus,44  herpes  simplex  virus,45  or  integrase-defective 
lentivirus.46,47
In conclusion, we succeeded in prolonged gene expression by 
co-transfection of pDNA containing the PB transposase expres-
sion cassette and pDNA containing PB IRs. The present study is 
an initial report that demonstrates PB-mediated sustained gene 
expression in vivo, and provides evidence that PB is a promising 
tool for various in vivo genetic applications such as gene therapies. 
In addition, the present study showed “overproduction inhibition” 
of PB in vivo, suggesting that optimization of the amount of PB 
transposase is necessary for high-level sustained gene expression. 
Improvement of both transposon systems and gene delivery meth-
ods will develop new therapy to overcome refractory diseases. We 
believe that the present study will encourage the development of 
PB-based vectors, and contribute to future basic genetic studies 
and studies of gene therapies.
MAterIAls And MetHods
Animals.  Female  ICR  mice  (5-week-old)  were  purchased  from  the 
Shizuoka Agricultural Cooperative Association for Laboratory Animals 
(Shizuoka, Japan). All the animals were housed with free access to food 
and water. The light (dark/light cycle was 2/12 hours), temperature, and 
humidity were kept constant throughout the experiments. All protocols 
for animal experiments were carried out with the approval of the Animal 
Experimentation Committee of the Graduate School of Pharmaceutical 
Sciences, Kyoto University.
pDNA  construction. To create pFerH-mcs, the portion of pVIVO2-mcs 
(InvivoGen, San Diego, CA) from the pMB1 replication origin to EF1polyA 
was amplified by PCR using primer1 and primer2 (primer sequences are 
listed below). The PCR fragment was purified, and self-ligated using Mighty 
Cloning Kit (blunt end) (Takara Bio, Ōtsu, Japan). To create pFerH-PBTP, 
PB transposase ORF was amplified using p3E1.2 (a gift from Prof. Hajime 
Mori, Kyoto Institute of Technology, Kyoto, Japan) as a template, and primer3 
and primer4. The PCR product was cloned into pFerH-mcs using In-Fusion 
PCR cloning kit (Takara Bio). The PCR product including PB transposon 
IRs (p3EIR) was created using p3E1.2 as a template, primer5, and primer6. 
The expression cassette including the firefly luciferase gene under CMV pro-
moter control and neomycin-resistance gene under SV40 promoter control 
was amplified by PCR using pCMV-luc as a template, primer7, and primer8. 
To create pIR-CMVluc, these two PCR products were ligated using Mighty 
Cloning Kit (blunt end). The expression cassette including Gluc gene under 
CMV promoter control was amplified by PCR using pCMV-Gluc Control 
Plasmid (New England BioLabs Japan, Tokyo, Japan) as a template, primer9, 
and primer10. This PCR product was ligated with p3EIR to create pIR-CM-
VGluc. hEF1 promoter was amplified by PCR using pBLAST49-hHGF as a 
template, primer11, and primer12. The PB transposon including the Gluc 
expression cassette without CMV promoter was created by PCR using pIR-
CMVGluc as a template, primer13, and primer14. To create pIR-hEF1Gluc, 
this PCR product was ligated with hEF1 promoter PCR product. To create 
pIR-blastHGF, pBLAST49-hHGF (InvivoGen) was digested by restriction 
enzyme SgfI and ligated with p3EIR using Mighty Cloning Kit (blunt end). 
KOD-FX or KOD-plus ver.2 (Toyobo, Osaka, Japan) was used for all PCRs, 
and High Pure PCR Product Purification Kit (Roche Diagnostics, Tokyo, 
Japan)  or  gel  indicator  DNA  extraction  kit  (Biodynamics  Laboratory, 
Tokyo, Japan) was used for purification of PCR products. All pDNAs were 
amplified in the E. coli strain DH5α, isolated and purified using QIAprep 
Spin Miniprep Kit (Qiagen, Tokyo, Japan) or JETSTAR 2.0 Plasmid Giga Kit 
(GenoMed, Lohne, Germany).
Primer1 TCTACAAATGTGGT 
ATGGAAATGTTAAT
Primer2 CAGCTTTCTATG 
CAACCCAAGGA
Primer3 TTCAAAGCAATCAT 
GATGGGTAGTTCT 
TTAGACGATGAGCA
Primer4 TAGGGATAATCCTA 
GTCAGAAACAACTT 
TGGCACATATCA
Primer5 AGAACTACCCATTT 
TATTATATATTAGTC 
ACGA
Primer6 AATACAACATGAC 
TGTTTTTAAAGTA 
CAAAAT
Primer7 TATTCGTCTTCCTAC 
TGCAGCAGGCTTTA 
CACTTTATGCTTCC
Primer8 GAACATTGTCAGA 
TCTCGATGTACGG 
GCCAGATATA
Primer9 CGATGTACG 
GGCCAGA 
TATACGC
Primer10 CAGAAAAGCATC 
TTACTTGGCATGA
Primer11 ACATTTCTCTATC 
GAAGGATCTGC
Primer12 CCGGTGATCT 
CAGGTAGGC
Primer13 ATGGGAGT 
CAAAGTTC 
TGTTTGC
Primer14 AATACAACATGA 
CTGTTTTTAAAG 
TACAAAAT
Primer15 TCGCGCGT 
TTCGGTGATG
Primer16 GACCCCGTAGAA 
AAGATCAAAGGA
Cell culture. HepG2 was maintained in Dulbecco’s modified Eagle’s essential 
medium containing 10% fetal bovine serum. Hep3B was maintained in Eagle’s 
minimum essential medium containing 2 mmol/l glutamine, 1% nonessential 
amino acids, 1 mmol/l sodium pyruvate, and 10% fetal bovine serum.Molecular Therapy  vol. 18 no. 4 apr. 2010  713
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In vitro transposition study. The indicated numbers of cells were seeded 
into individual wells of 6- or 12-well plates 18 hours before transfection. 
Cells were transfected with the indicated amount of pDNA by FuGENE6 
(Roche Diagnostics). Two days after transfection, cells were harvested, and 
1/10~1/100th of the cells were transferred to 100 mm plates or 6-well plates, 
and maintained in medium containing 800 µg/ml G418 (Nacalai Tesque, 
Kyoto, Japan) for 2 weeks. For luciferase imaging, 0.3 mmol/l d-luciferin 
(Promega, Tokyo, Japan) in PBS was added to the cells, and then lumi-
nescence was captured for 5 minutes using a NightOwl NC320 Molecular 
Light Imager (Berthold Technologies, Bad Wildbad, Germany). To count 
G418-resistant colonies, cells were fixed with 4% paraformaldehyde in PBS 
(Wako Pure Chemical Industries, Osaka, Japan) for 10 minutes and stained 
with 0.2% methylene blue (Wako Pure Chemical Industries) in PBS. The 
numbers of colonies were corrected by the dilution ratio.
Cell viability assay. Hep3B (1 × 104) cells were seeded into individual wells 
of 96-well plates 18 hours before transfection. Cells were transfected with 
the indicated amount of pDNA by FuGENE6. Two days after transfection, 
viability was determined using Cell Counting Kit-8 (Dojindo Laboratories, 
Kumamoto, Japan).
Plasmid excision assay in vitro. Hep3B and HepG2 (2 × 105) cells were 
seeded into individual wells of 6-well plates 18 hours before transfection. 
Cells were transfected with 0.67 µg pIR-CMVluc and 0.33 µg pFerH-PBTP 
of pFerH-mcs. Two days after transfection, cells were harvested, and DNA 
was  isolated  using  Genelute  mammalian  genomic  DNA  extraction  kit 
(Sigma-Aldrich Japan, Tokyo, Japan). PCR amplification was performed 
using the isolated DNA as templates, primer15, primer16, and PrimeSTAR 
GXL DNA Polymerase (Takara Bio) PCR products were electrophoresed 
on 1% agarose S (Nippon Gene, Tokyo, Japan) gel.
Analysis  of  transposon-chromosome  junctions  via  plasmid  rescue. 
Hep3B (2 × 105) cells were seeded into individual wells of 6-well plates 
18  hours  before  transfection.  Cells  were  transfected  with  0.67 µg  pIR-
blastHGF  and  0.33 µg  pFerH-PBTP.  Two  days  after  transfection,  cells 
were harvested, transferred to 100 mm plates and propagated in medium 
containing  3 µg/ml  blasticidin  S  (InvivoGen).  DNA  was  isolated  from 
these cells using Genelute mammalian genomic DNA extraction kit, and 
digested by restriction enzyme BglII (Takara Bio) and BamHI (Toyobo). 
After digestion by restriction enzymes, DNA was purified using High Pure 
PCR  Product  Purification  Kit  and  ligated  using  Ligation-Convenience 
Kit (Nippon Gene). The ligation products were used to transform E. coli 
Competent Quick DH5α (Toyobo) or E. coli HST08 Premium Competent 
Cells (Takara Bio). pDNA was isolated and purified using QIAprep Spin 
Miniprep  Kit.  Nucleotide  sequences  of  the  pDNA  were  sequenced  by 
Fasmac sequencing service (Fasmac, Atsugi, Japan). UC Santa Cruz BLAT 
was used to map PB integration sites.
Assay of firefly luciferase activity in liver. Mice were injected intrave-
nously via the tail vein with 1.6 ml saline containing the indicated amount 
of pDNA. At the indicated time points, mice were killed, and livers were 
harvested.  The  livers  were  homogenized  by  adding  lysis  buffer  (0.05% 
Triton X-100, 2 mmol/l EDTA, 0.1 mol/l Tris, pH 7.8). The homogenate 
was centrifuged at 16,060 g for 10 minutes at 4 °C. The firefly luciferase 
activity of the supernatant was measured using Picagene luciferase sub-
strate (Toyo Ink, Tokyo, Japan) and Lumat LB 9507 (EG&G Berthold, Bad 
Wildbad, Germany).
Assay of Gluc activity in serum. Mice were injected intravenously via 
the  tail  vein  with  1.6 ml  saline  containing  the  indicated  amount  of 
pDNA. At the indicated time points, blood was collected via the tail 
vein. The blood samples were put on ice for 30 minutes and centrifuged 
at 16,060 g for 10 minutes at 4 °C. The Gluc activity of the supernatant 
was measured using Gluc assay kit (New England BioLabs Japan) and 
Lumat LB 9507.
Plasmid excision assay in vivo. Mice were injected intravenously via the 
tail vein with 1.6 ml saline containing the 25 µg pIR-EF1Gluc, and 25 µg 
pFerH-PBTP or pFerH-mcs. Three days after injection, livers were har-
vested, and DNA was isolated using Genelute mammalian genomic DNA 
extraction kit. PCR amplification was performed using the isolated DNA 
as templates, primer15, primer16, and PrimeSTAR GXL DNA Polymerase 
PCR products were electrophoresed on 1% agarose S gel.
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